Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96J01
UPID:
THOC3_HUMAN
Alternative names:
TEX1 homolog; hTREX45
Alternative UPACC:
Q96J01; Q6NZ53
Background:
THO complex subunit 3, also known as TEX1 homolog or hTREX45, plays a pivotal role in mRNA processing and export. It is a component of the THO subcomplex within the TREX complex, crucial for the efficient export of polyadenylated RNA and spliced mRNA. This protein facilitates the coupling of mRNA transcription, processing, and nuclear export, specifically associating with spliced mRNA to promote its export via the TAP/NFX1 pathway.
Therapeutic significance:
Understanding the role of THO complex subunit 3 could open doors to potential therapeutic strategies.